Autobahn Therapeutics, a San Diego, CA-based biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, raised $100M in Series C funding.
The round was led by Newpath Partners with participation from new investors Canaan Partners, Monograph Capital, Insight Partners, and existing investors.
The company intends to use the funds to commence two Phase 2 clinical trials for its lead program, ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist that was well-tolerated and demonstrated CNS target engagement in a Phase 1 study.
Led by CEO and President Kevin Finney, Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. It aims to improve new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression.
FinSMEs
25/07/2024